search icon
      blog search icon

      AQST Stock Price History and Quote Analysis: Insights for Investors

      Aquestive Therapeutics, Inc.

      (NASDAQ:AQST)

      $1.97

      -0.13 (-6.19%)

      At Close: 4:00 PM

      AQST Stock Price Graph

      • 1D
      • 5D
      • 1M
      • 3M
      • 6M
      • 1Y
      • YTD
      • All

      AQST Stock Price Today

      Aquestive Therapeutics, Inc. (AQST) stock declined over -8.37% intraday to trade at $1.97 a share on NASDAQ. The stock opened with a loss of -33.81% at $1.39 and touched an intraday high of $1.52, falling -6.19% against the last close of $2.10. The Aquestive Therapeutics, Inc. in stock market went to a low of $1.38 during the session.

      AQST Stock Snapshot

      $2.10

      Prev. Close

      131.54 Million

      Market Cap

      $1.38

      Day Low

      $1.39

      Open

      N/A

      Number of Shares

      $1.52

      Day High

      N/A

      P/E ratio

      -0.25

      EPS (TTM)

      0.37

      Cash Flow per Share

      N/A

      Free Float in %

      -1.54

      Book Value

      708804.00

      Volume

      AQST Stock Price History Chart

      DateOpenHighLowCloseVolume

      Contact Details

      30 Technology Drive
      Warren, NJ 07059
      US

      Website:https://www.aquestive.com

      Contact #:908 941 1900

      Company Information

      EmployeesN/A

      BetaN/A

      Sales or Revenue$48.06 Million

      5Y Sales Change-5.88%

      Fiscal Year EndsDec. 2022

      SectorHealthcare

      IndustryDrug Manufacturers—Specialty & Generic

      About Company

      Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

      Peers

      Frequently Asked Questions

      icon

      What is the current Aquestive Therapeutics, Inc. (AQST) stock price?

      Aquestive Therapeutics, Inc. (NASDAQ: AQST) stock price is $1.97 in the last trading session. During the trading session, AQST stock reached the peak price of $1.52 while $1.38 was the lowest point it dropped to. The percentage change in AQST stock occurred in the recent session was -8.37% while the dollar amount for the price change in AQST stock was -$0.18.

      icon

      AQST's industry and sector of operation?

      The NASDAQ listed AQST is part of Drug Manufacturers—Specialty & Generic industry that operates in the broader Healthcare sector. Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally.

      icon

      Who are the executives of AQST?

      Dr. Stephen Wargacki
      Senior Vice President of R&D
      Mr. Peter E. Boyd
      Senior Vice President of Bus. Process & Information Technology
      Mr. Robert Charles Arnold
      Vice President of Fin., Controller & Assistant Sec.
      Mr. Daniel Barber
      Chief Executive Officer, Pres & Director

      icon

      How AQST did perform over past 52-week?

      AQST's closing price is 2.17% higher than its 52-week low of $0.72 where as its distance from 52-week high of $2.69 is -0.01%.

      icon

      How many employees does AQST have?

      Number of AQST employees currently stands at N/A. AQST operates from 30 Technology Drive, Warren, NJ 07059, US.

      icon

      Link for AQST official website?

      Official Website of AQST is: https://www.aquestive.com

      icon

      How do I contact AQST?

      AQST could be contacted at phone #908 941 1900 and can also be accessed through its website. AQST operates from 30 Technology Drive, Warren, NJ 07059, US.

      icon

      How many shares of AQST are traded daily?

      AQST stock volume for the day was 708804.00 shares. The average number of AQST shares traded daily for last 3 months was 309.82 Thousands.

      icon

      What is the market cap of AQST currently?

      The market value of AQST currently stands at $131.54 Million with its latest stock price at $1.97 and N/A of its shares outstanding.